Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma

Next Previous
Trial Profile

A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rigosertib (Primary) ; Rigosertib (Primary)
  • Indications Epidermolysis bullosa dystrophica; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 12 Oct 2023 Results presented in an Onconova Therapeutics media release.
    • 12 Oct 2023 According to an Onconova Therapeutics media release, data from this study will be presented today in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV).
    • 05 Jun 2023 According to an Onconova Therapeutics media release, Trial in Progress poster detailed design of this trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place June 2 - 6, 2023 in Chicago, Illinois and online.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top